Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

New temporary pacing system for TAVR launches in US
New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.
AI-powered EHR alerts make a world of difference for cardiologists, heart patients
AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.
PCI before TAVR? In older CAD patients, deferral may be the best approach
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
FDA clears new AI software for mitral valve repair
Philips worked closely with Edwards Lifesciences to develop the new software.

The SoloPace Fusion Temporary Pacing System from Solo Pace Inc. is deigned to eliminate the need for right ventricular (RV) lead placement, which requires the added procedural step to gaining venous access. This can cut procedure time and mitigate possible complication risks. For interventional cardiologists using improvised left ventricular (LV) pacing, this system can replace ad-hoc clip assemblies, subcutaneous needles and exposed wire connections, which are known sources of inconsistent pace capture.

New temporary pacing system for TAVR launches in US

New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Adam Greenbaum, MD, presents late-breaking data at ACC.26.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.

Philips has secured U.S. Food and Drug Administration (FDA) clearance for EchoNavigator R5.0 with DeviceGuide, the company’s artificial intelligence (AI)-enabled software for mitral transcatheter edge-to-edge repair (M-TEER).

FDA clears new AI software for mitral valve repair

Philips worked closely with Edwards Lifesciences to develop the new software.

When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.

Cleveland Clinic launches partnership focused on AI-powered TAVR planning

Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.

FDA-approved surgical aortic valve implanted for first time in US

The next-generation valve from Corcym features a sutureless frame as well as laser-cut leaflets and thread holes.